BioSpace News Archive

Kronos Bio, Inc. (Nasdaq: KRON) announced today that it has entered into a discovery collaboration in the field of oncology with Genentech, a member of the Roche Group, focused on discovering and developing small-molecule drugs that modulate transcription factor targets selected by Genentech.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced recent commercial and regulatory accomplishments and outlined key 2023 milestones, highlighting the strong potential of its hematopoietic stem cell (HSC) gene therapy platform to drive value for patients, providers and shareholders.

Spexis AG announced the successful completion of the first-in-human clinical trial with novel class antibiotic murepavadin, delivered via the oral inhalation route.

Alentis Therapeutics, the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, announces positive results from a single ascending dose Phase 1 study of its lead program, ALE.F02, currently in development for the treatment of advanced kidney, lung and liver fibrosis.

Nicox SA announced its intention to move its listing from the Euronext Paris regulated market to Euronext Growth Paris and convened for this purpose an ordinary shareholder meeting on Tuesday February 14, 2023 at 2:00 pm CEST in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne - France.

Masimo announced the results of a prospective study published in the American Journal of Emergency Medicine in which Dr. Zohair Ahmed Ali Al Aseri and colleagues at King Saud University Medical City and Dar Al Uloom University evaluated the performance of noninvasive spot-check hemoglobin measurement with Masimo SpHb® on emergency department patients.

Hemogenyx Pharmaceuticals plc announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor platform technology, designed to program immune cells to eliminate viral infections by destroying the viruses that cause them.

Orexo AB, announces the company has initiated two exploratory feasibility studies, applying the proprietary drug delivery platform amorphOX® to protein based pharmaceuticals and vaccines in collaboration with leading international biopharmaceutical and vaccine companies.

Servier and Aqemia announce the extension of their new-molecule discovery collaboration on an undruggable therapeutic target in immuno-oncology.

Regenative Labs (Regenative), a leading HCT/P manufacturer has published a case study in the Journal of Biomedical Research and Environmental Sciences alongside Dr. Alan Meglin, of Advanced Regenerative Therapy in Georgia.